Tenascin patterns of expression in duct carcinoma in situ of the breast

Annals of Clinical and Laboratory Science

Volumn 30, Issue 3, 2000, Pages 266-271

  Iskaros, B F ^a   Sison, C P ^a   Hajdu, S I ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Adhesion glycoprotein; Breast carcinoma; Duct carcinoma in situ; Extracellular matrix; Tenascin

Indexed keywords

GLYCOPROTEIN; MONOCLONAL ANTIBODY; TENASCIN;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CARCINOMA IN SITU; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

BIOPSY; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MASTECTOMY, SEGMENTAL; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; TENASCIN;

EID: 0033861072     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tenascin: An extracellular matrix protein prominent in specialized embryonic tissues and tumors
2. Hexabrachion protein (tenascin, cytotactin, brachionectin) in connective tissues, embryonic brain and tumors
3. Tenascin is a stromal marker for epithelial malignancy in the mammary gland
4. Differential distribution of tenascin in the normal, hyperplastic and neoplastic breast
5. Extra-cellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast
6. Cytokines in context
7. Human breast precancer: Cancer status
8. Mammographic detection of early breast cancer: Ten years experience in a community hospital
9. Non-invasive breast carcinoma: Results of a national survey of the American College of Surgeons
10. Ductal carcinoma in situ (intraductal carcinoma) of the breast
11. Significance and staging of nonpalpable carcinomas of the breast
12. Mammographically detected duct carcinoma in situ
13. ABC of breast diseases. Carcinoma in situ and patients at high risk of breast cancer
14. Duct carcinoma in situ: 227 Cases without microinvasion
15. Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma
16. Heterogeneity of intraductal carcinoma of the breast
17. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions
18. Duct carcinoma in situ of the breast: Reproducibility of histological subtype analysis
19. Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer
20. Tenascin staining positivity and the survival of patients with invasive breast carcinoma
21. Morphologic pattern of tenascin as a diagnostic biomarker in colon cancer
22. Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma
23. Participation of tenascin and transforming growth factor beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts
24. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastasis, and short-term treatment failure
25. Predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis